Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

microRNAs may help predict survival in liver cancer

Tiny molecules that help cells regulate which proteins they make might one day help doctors predict which liver-cancer patients are likely to live longer than others, new research suggests.

4 Feb 2008

Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer

As the incidence of liver cancer continues to grow - fueled in large part, by rising rates of hepatitis C infections - so too does the need for tests to help diagnose the disease at an earlier stage.

16 Jan 2008

New biomarker for predicting liver cancer spread and survival discovered

New research has shown that a unique pattern of microRNAs, small RNA molecules that regulate gene activity, can accurately predict whether liver cancer will spread and whether liver cancer patients will have shorter or longer survival, even patients with early stage disease.

7 Jan 2008

Gene variation increases risk of liver tumor in patients with cirrhosis

A particular gene variation appears to significantly increase the risk that individuals with cirrhosis of the liver will go on to develop hepatocellular carcinoma (HCC), a liver tumor that is the third leading cause of cancer death.

2 Jan 2008

Corgenix Medical enters development agreement wth NIH

Corgenix Medical Corporation has announced it has entered into a corporative research and development agreement (CRADA) with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

18 Dec 2007

U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable.

19 Nov 2007

New target for Hepatocellular carcinoma therapy

Hepatocellular carcinoma (HCC) is a major health problem worldwide. Currently, the only chance for obtaining a cure in patients with HCC is by either a surgical resection or liver transplantation.

25 Oct 2007

Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma

Portal venous tumor thrombus (PVTT) is a crucial factor that can worsen the prognosis of patients with hepatocellular carcinoma (HCC).

18 Oct 2007

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

16 Oct 2007

Proteins found that could be used to improve diagnosis of hepatocellular carcinoma

Researchers report in the October 2007 issue of Molecular & Cellular Proteomics that they have identified proteins that could be used to improve the diagnosis of hepatocellular carcinoma, the most common type of liver cancer.

8 Oct 2007

FDA fast tracks PI-88 for the treatment of post resection liver cancer

Progen Pharmaceuticals Limited has announced that its investigational anti-cancer drug PI-88 has been awarded Fast Track status by the U.S. Food and Drug Administration (FDA).

25 Sep 2007

Nerve growth factor positively related with liver cancer - potential therapy target

Nerve growth factor (NGF), as the name says, is an essential peptide factor for the growth and differentiation of neuronal cells.

20 Sep 2007

Liver cancer marker could yield blood test for early detection

In the face of an emerging liver cancer crisis in Asia, researchers at the Chinese University of Hong Kong have developed a test that could help millions.

18 Sep 2007

New test to detect early stage liver cancer

Cancer of the liver is very difficult to detect, and it is a major cause of death in Asia and Africa, with rising incidence in Western countries as well.

9 Aug 2007

Coffee and liver cancer

After lung and stomach cancer, liver cancer is the third largest cause of cancer deaths in the world.

2 Aug 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007

New contributor to aggressive cancers

Mutations in the cell adhesion molecule known as integrin alpha 7 (integrin 7) lead to unchecked tumor cell proliferation and a significantly higher incidence in cancer spread, or metastasis, in several cancer cell lines, report researchers at the University of Pittsburgh School of Medicine in a study published in the Journal of the National Cancer Institute.

8 Jun 2007

Liver cancer patients with high serum levels of hepatitis B virus face poorer outcomes

In the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD), researchers report their findings from the first-ever study examining the prognostic value of serum HBV DNA levels for patients with liver cancer undergoing chemotherapy.

3 Jun 2007

Percutaneous radiofrequency ablation of liver tumors safe and effective

Percutaneous imaging guided radiofrequency ablation (RFA) of hepatocellular carcinoma is a safe and effective technique, with benefits such as reduced post-procedural pain and length of hospital stay, according to a study conducted by researchers from Changi General Hospital in Singapore.

8 May 2007